title: Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
abstract: Overactive bladder (OAB) is a condition defined by its symptoms--urinary urgency with or without urgency urinary incontinence and often with frequency and nocturia. As such, determining the efficacy of OAB treatments using objective measures, such as urodynamic testing, can be difficult. A better means of gauging treatment efficacy for symptom-based conditions is through the use of patient-reported outcomes (PROs). With PROs, clinicians can gain insight into how a treatment affects a patient's symptoms and whether improvement in symptoms has a positive effect from the patient's perspective. PROs are increasingly being included as end points in clinical trials, including those of antimuscarinic drugs for OAB. Consequently, clinicians should become familiar with the most commonly used instruments. We provide an overview of instruments used to assess symptoms, health-related quality of life, and treatment satisfaction in patients with OAB and discuss how PROs can be incorporated into clinical trial protocols.
authors.affiliation: Department of Obstetrics, Loyola University Medical Center, Maywood, Illinois 60153, USA. lbrubaker@lumc.edu
authors.forename: Linda
authors.initials: L
authors.lastname: Brubaker
authors.forename: Christopher
authors.initials: C
authors.lastname: Chapple
authors.forename: Karin S
authors.initials: KS
authors.lastname: Coyne
authors.forename: Zoe
authors.initials: Z
authors.lastname: Kopp
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003408:Cresols / Q000627:therapeutic use; D006304:Health Status; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D010349:Patient Compliance; D017060:Patient Satisfaction; D010665:Phenylpropanolamine / Q000627:therapeutic use; D011788:Quality of Life; D011812:Quinuclidines / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D014550:Urinary Incontinence, Stress / Q000628:therapy
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin; D000069464:Solifenacin Succinate